Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies

Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies

TAMPA, Fla. and SEATTLE – Moffitt Cancer Center announced today a licensing agreement with TuHURA Biopharma, Inc., a start-up biotechnology company in Seattle, to develop new immunotherapy treatments for cancer that will apply to a greater number of cancers and a larger patient population.

Full Story

Related posts

No visits? No problem: FSU researchers find incarcerated juveniles still optimistic about future

A new study by Florida State University researchers taps into the vastly unexplored area of…

Moffit: Therapeutic Strategies Based on Evolutionary Principles May Be Key to Improving Patient Outcomes

TAMPA, Fla. – For over a century, cancer treatment research has primarily focused on developing…

UM: Two Sylvester Pancreatic Cancer Researchers Awarded Grants

Cigarette smoking is one of the major risk factors for pancreatic cancer and a focus…